Drug intelligence / Profile preview

AXT-2008

Development stage: Unknown
Lead developer: Axter Therapeutics
Modality: Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

AXT-2008 is a combination therapy developed by Axter Therapeutics for the treatment of various cancers, including relapsed/refractory Hodgkin lymphoma, non-small cell lung cancer (NSCLC), and other advanced malignant solid tumors. It consists of AXT-1003, a small molecule inhibitor of Enhancer of Zeste Homolog 2 (EZH2), and an anti-PD-1 monoclonal antibody. The combination aims to leverage the epigenetic modulating effects of EZH2 inhibition to enhance the efficacy of PD-1 immune-checkpoint blockade, potentially overcoming resistance to immunotherapy. It is currently in Phase 1/2 clinical development.

Other names: AXT-1003 + anti-PD-1

Targets

EZH2 (Histone-lysine N-methyltransferase EZH2)PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on AXT-2008.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AXT-2008.

Explore the full profile